Foghorn Therapeutics raises $50 million in January financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St rises as softer jobs data calms rate-hike fears
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Wall Street ends choppy session lower as tech shares drop
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
March 11, 2026 4:09 PM EDTFHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026
Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)
Completed a $50Â million registered direct financing in January 2026
Strong balance sheet with cash, cash equivalents, and marketable... More
